CA3118629A1 - Methods of treating diabetes in severe insulin-resistant diabetic subjects - Google Patents

Methods of treating diabetes in severe insulin-resistant diabetic subjects Download PDF

Info

Publication number
CA3118629A1
CA3118629A1 CA3118629A CA3118629A CA3118629A1 CA 3118629 A1 CA3118629 A1 CA 3118629A1 CA 3118629 A CA3118629 A CA 3118629A CA 3118629 A CA3118629 A CA 3118629A CA 3118629 A1 CA3118629 A1 CA 3118629A1
Authority
CA
Canada
Prior art keywords
test material
subject
hfd
pharmaceutically acceptable
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3118629A
Other languages
English (en)
French (fr)
Inventor
Helena Edlund
Bjorn Eriksson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Balticgruppen Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balticgruppen Bio AB filed Critical Balticgruppen Bio AB
Publication of CA3118629A1 publication Critical patent/CA3118629A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3118629A 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects Pending CA3118629A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2018/053203 WO2020095010A1 (en) 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects

Publications (1)

Publication Number Publication Date
CA3118629A1 true CA3118629A1 (en) 2020-05-14

Family

ID=64332106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3118629A Pending CA3118629A1 (en) 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects

Country Status (5)

Country Link
US (1) US20220023269A1 (https=)
JP (2) JP7432598B2 (https=)
AU (2) AU2018448511B2 (https=)
CA (1) CA3118629A1 (https=)
WO (1) WO2020095010A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910092D0 (en) * 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
CN113117241B (zh) * 2021-04-15 2022-01-28 中国科学院合肥物质科学研究院 一种提高胰岛素水平和敏感性的磁场发生装置及其应用
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
EP1706108A4 (en) 2003-12-30 2009-08-12 Md Bioalpha Co Ltd TREATMENT OF FAT AND METABOLIC SYNDROME WITH TRANSHINONE DERIVATIVES FOR INCREASING METABOLISM ACTIVITY
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
EP3050567B1 (en) 2013-09-26 2020-11-04 Energenesis Biomedical Co., Ltd. Compound for activating ampk and uses thereof
KR101986983B1 (ko) 2015-01-07 2019-06-07 창저우 더저 메디컬 사이언스 컴퍼니.,리미티드 망기페린-6-ｏ-베르베린염 수화물 및 그 제조방법과 용도
AU2017205795A1 (en) 2016-01-05 2018-07-05 Nrl Pharma, Inc. Ascochlorin derivative and use thereof as AMPK activator

Also Published As

Publication number Publication date
JP2022517483A (ja) 2022-03-09
WO2020095010A1 (en) 2020-05-14
AU2025238101A1 (en) 2025-11-13
JP7432598B2 (ja) 2024-02-16
US20220023269A1 (en) 2022-01-27
JP7755618B2 (ja) 2025-10-16
AU2018448511B2 (en) 2025-07-03
JP2023116697A (ja) 2023-08-22
AU2018448511A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
AU2018448511B2 (en) Methods of treating diabetes in severe insulin-resistant diabetic subjects
US9421208B2 (en) Methods for the treatment of solid tumors
Ndisang Role of heme oxygenase in inflammation, insulin‐signalling, diabetes and obesity
Tousoulis et al. Diabetes mellitus and vascular endothelial dysfunction: current perspectives
Lavie et al. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link
Waugh et al. Pioglitazone: a review of its use in type 2 diabetes mellitus
ES2433476T3 (es) Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
ES2959842T3 (es) Combinación de un agonista de PPAR con un agonista de FXR
AU2018392987A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
US8299083B2 (en) PDE5 inhibitor compositions and methods for treating cardiac indications
JP7749593B2 (ja) 褐色脂肪生成を誘導する方法及び組成物
CN102548553B (zh) 用于治疗糖尿病酮酸中毒的方法和组合物
TW202317109A (zh) 控制血糖值之方法及糖尿病與相關病症之治療
Nishiyama et al. Protective effects of imeglimin and metformin combination therapy on β-cells in db/db male mice
Alghamdi et al. An overview on the role of xanthine oxidase inhibitors in gout management
JP7466534B2 (ja) 代謝性疾患及び／又はその臨床状態を抑制及び／又は処置するための組成物及び方法
Peng et al. Riboflavin ameliorates pathological cardiac hypertrophy and fibrosis through the activation of short-chain acyl-CoA dehydrogenase
Li et al. Protective effects of moderate intensity static magnetic fields on diabetic mice
Dutta et al. Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy
Zhao et al. Tolerability, safety, pharmacokinetics, and pharmacodynamics of SY-004, a glucokinase activator, in healthy Chinese adults: a randomized, phase Ia, single-ascending dose study
US20110160219A1 (en) Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient
Han et al. ICS II protects against cardiac hypertrophy by regulating metabolic remodelling, not by inhibiting autophagy
Gupte et al. Animal models of haploinsufficiency revealed the isoform-specific role of GSK-3 in HFD-induced obesity and glucose intolerance
US20100056460A1 (en) Combination of organic compounds
US20240398808A1 (en) Dihydrofolate for hypoglycemic activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231103

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241030

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250114

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED

Effective date: 20250204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250424

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20260108